logo
Twitter
Discord
Email
logo
Cryoport, Inc.

Cryoport, Inc.

NASDAQ•CYRX
CEO: Mr. Jerrell W. Shelton
Sector: Industrials
Industry: Integrated Freight & Logistics
Listing Date: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
Contact Information
112 Westwood Place, Suite 350, Brentwood, TN, 37027, United States
949-470-2300
www.cryoportinc.com
Market Cap
$503.67M
P/E (TTM)
7.5
30.6
Dividend Yield
--
52W High
$11.44
52W Low
$4.58
52W Range
80%
Rank69Top 93.9%
1.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2024 Data

Revenue

$44.23M-21.94%
4-Quarter Trend

EPS

-$0.18+637.19%
4-Quarter Trend

FCF

-$1.27M+20.36%
4-Quarter Trend

2024 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenue $44.2M USD for Q3, up 15.4% from $38.3M USD. Life Sciences Services revenue grew 15.9%.
Gross Margin Expansion Noted Nine months gross margin reached 46.9% USD, a 22.3% increase over prior period. Cost of revenue grew slower.
Cash Position Significantly Improved Cash and equivalents $255.8M USD as of September 30, 2025, reflecting proceeds from CRYOPDP divestiture.
Continuing Operations Loss Narrowed Nine months loss from continuing operations $(25.4M) USD, significantly better than prior year's $(87.5M) USD loss.

Risk Factors

Continuing Operations Remain Unprofitable Q3 loss from continuing operations was $(6.7M) USD, indicating ongoing profitability challenges outside divestiture gains.
Goodwill Impairment Potential MVE reporting unit goodwill fully impaired in 2024 due to sustained share price decrease and performance concerns.
Future Capital Funding Required Management recognizes need for additional capital via equity or debt to fund operations until sustained profitability.
Foreign Exchange Fluctuation Exposure Foreign currency risk exists on cash balances; 20% adverse change could impact cash by $5.0M USD.

Outlook

Divestiture Strategic Shift Complete Completed CRYOPDP divestiture for $133.0M USD, enhancing focus on EMEA/APAC growth strategy alignment.
Focus on Core Life Sciences Strategy emphasizes supporting Cell and Gene Therapy development through advanced logistics and product offerings.
Share Repurchase Authorization Available Approximately $65.9M USD repurchase authorization remains available under existing Repurchase Programs as of period end.
Investment in Growth Initiatives Expect to incur significant expenses near term for new supply chain initiatives and geographic expansion efforts.

Peer Comparison

Revenue (TTM)

Forward Air CorporationFWRD
$2.50B
+14.5%
Titan International, Inc.TWI
$1.80B
-2.8%
Universal Logistics Holdings, Inc.ULH
$1.64B
-7.5%

Gross Margin (Latest Quarter)

ZipRecruiter, Inc.ZIP
89.3%
-0.2pp
Cryoport, Inc.CYRX
48.2%
+3.4pp
Ennis, Inc.EBF
30.5%
+0.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
FWRD$812.07M-6.9-71.5%16.9%
TWI$537.75M-87.8-1.1%33.0%
ZIP$512.29M-14.0284.6%2.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-9.4%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 3, 2026
|
EPS:-$0.19
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $44.23M-21.9%
    |
    EPS: $-0.18+637.2%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $45.45M+14.5%
    |
    EPS: $2.05-226.5%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $41.04M-24.8%
    |
    EPS: $-0.28-34.9%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2024|Filed: Mar 7, 2025|
    Revenue: $233.26M-2.1%
    |
    EPS: $-2.21-12.7%
    Miss
  • Form 10-Q - Q3 2023

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $56.66M+0.9%
    |
    EPS: $-0.02-92.2%
    Beat
  • Form 10-Q - Q2 2023

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $39.71M-30.4%
    |
    EPS: $-1.62+285.7%
    Miss
  • Form 10-Q - Q1 2023

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $54.59M-13.1%
    |
    EPS: $-0.43+168.8%
    Miss
  • Form 10-K - FY 2022

    Period End: Dec 31, 2023|Filed: Mar 13, 2024|
    Revenue: $233.26M-1.7%
    |
    EPS: $-2.21-137.6%
    Miss